Moderna shares fall despite promising data from cancer vaccine trial
[ad_1] Sopa Images | Lightrocket | Getty Images Shares of Moderna fell Monday as Wall Street chewed over new trial results on the personalized cancer vaccine it is developing with Merck. Merck’s shares were relatively flat. The experimental mRNA vaccine, when combined with Merck’s blockbuster drug Keytruda, cut the risk of recurrence of skin cancer…